Related Experiment Videos
[Glitazones (thiazolidinedione)]
Revue Medicale De Bruxelles
|December 8, 2000
Summary
Thiazolidinediones (TZD) are a new class of drugs that improve insulin sensitivity in type 2 diabetes by activating PPAR gamma. While effective in lowering glucose and lipids, potential liver toxicity requires careful monitoring.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Insulin resistance is a primary defect in type 2 diabetes mellitus.
- Thiazolidinediones (TZD) represent a novel class of insulin-sensitizing agents.
- TZDs function by activating Peroxisome Proliferator Activated Receptor gamma (PPARγ).
Purpose of the Study:
- To evaluate the efficacy and safety of thiazolidinediones (TZD) in managing type 2 diabetes.
- To assess the impact of TZDs on glycemic control and lipid profiles.
- To identify potential adverse effects associated with TZD therapy.
Main Methods:
- Review of clinical trial data for TZD medications.
- Analysis of effects on plasma glucose, insulin, and HbA1c levels.
- Evaluation of TZD interactions with other antidiabetic agents and impact on lipid parameters.
Main Results:
- TZDs significantly decrease plasma glucose, insulin, and HbA1c.
- They demonstrate synergistic effects with biguanides, sulfonylureas, and insulin.
- TZDs reduce triglycerides and LDL oxidation while increasing HDL cholesterol.
- Adverse effects include hepatic dysfunction (approx. 2% with troglitazone), fluid retention, and potential colon polyp induction.
Conclusions:
- Thiazolidinediones show promise in type 2 diabetes therapy due to their insulin-sensitizing and lipid-modulating properties.
- Potential for significant role in diabetes management, pending long-term efficacy and safety data.
- Second-generation TZDs (rosiglitazone, pioglitazone) may have a lower incidence of severe side effects like liver failure compared to first-generation agents.